Development of radiographic classification criteria for hand osteoarthritis: a methodological report (Phase 2).

Autor:	Haugen IK; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway ida.k.haugen@gmail.com., Felson D; Rheumatology section, Boston University School of Medicine, Boston, Massachusetts, USA.; Arthritis Research UK Epidemiology Unit, National Institute for Health Research Biomedical Research Centre, The University of Manchester, Manchester, UK., Abhishek A; Academic Rheumatology, School of Medicine, University of Nottingham, Nottingham, UK.; NIHR Nottingham Biomedical Research Centre, Nottingham, UK., Berenbaum F; INSERM CRSA, Sorbonne University, Paris, France.; Department of Rheumatology, Hopital Saint-Antoine, Paris, France., Edwards JJ; Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, UK., Herrero Beaumont G; Department of Rheumatology, Instituto de Investigación Sanitaria Fundación Jimenez Díaz, Universidad Autonoma de Madrid, Madrid, Spain., Hermann-Eriksen M; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway., Hill CL; Rheumatology Department, Queen Elizabeth Hospital, Woodville, South Australia, Australia.; Faculty of Health and Medical Sciences, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia., Ishimori M; Department of Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA., Jonsson H; Department of Rheumatology, Landspitali, Reykjavik, Iceland., Karjalainen T; Department of Surgery, Central Finland Central Hospital, Jyväskylä, Finland., Leung YY; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore., Maheu E; Department of Rheumatology, Hopital Saint-Antoine, Paris, France., Mallen CD; Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, UK., Moe RH; National Advisory Unit on Rehabilitation in Rheumatology, Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway., Ramonda R; Rheumatology Unit, Department of Medicine, University of Padua, Padova, Italy., Ritschl V; Section for Outcomes Research, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Wien, Austria.; Institute for Arthritis and Rehabilitation, Ludwig Boltzmann Gesellschaft, Wien, Austria., Stamm TA; Section for Outcomes Research, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Wien, Austria.; Institute for Arthritis and Rehabilitation, Ludwig Boltzmann Gesellschaft, Wien, Austria., Szekanecz Z; Division of Rheumatology, University of Debrecen, Debrecen, Hungary., van der Giesen FJ; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands., Ritt MJPF; Department of Plastic, Reconstructive and Hand Surgery, Amsterdam UMC, Amsterdam, The Netherlands., Wittoek R; Department of Rheumatology, Ghent University, Ghent, Belgium., Kjeken I; National Advisory Unit on Rehabilitation in Rheumatology, Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway., Osteras N; National Advisory Unit on Rehabilitation in Rheumatology, Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway., van de Stadt LA; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands., Englund M; Clinical Epidemiology Unit, Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden., Dziedzic KS; Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, UK., Marshall M; Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, UK., Bierma-Zeinstra S; Department of General Practice, Erasmus University Rotterdam, Rotterdam, The Netherlands., Hansen P; Department of Economics, University of Otago, Dunedin, New Zealand., Greibrokk E; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway., Smeets W; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands., Kloppenburg M; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
Jazyk:	angličtina
Zdroj:	RMD open [RMD Open] 2022 Feb; Vol. 8 (1).
DOI:	10.1136/rmdopen-2021-002024
Abstrakt:	Objectives: In Phase 1 of developing new hand osteoarthritis (OA) classification criteria, features associated with hand OA were identified in a population with hand complaints. Radiographic findings could better discriminate patients with hand OA and controls than clinical examination findings. The objective of Phase 2 was to achieve consensus on the features and their weights to be included in three radiographic criteria sets of overall hand OA, interphalangeal OA and thumb base OA. Methods: Multidisciplinary, international expert panels were convened. Patient vignettes were used to identify important features consistent with hand OA. A consensus-based decision analysis approach implemented using 1000minds software was applied to identify the most important features and their relative importance influencing the likelihood of symptoms being due to hand OA. Analyses were repeated for interphalangeal and thumb base OA. The reliability and validity of the proposed criteria sets were tested. Results: The experts agreed that the criteria sets should be applied in a population with pain, aching or stiffness in hand joint(s) not explained by another disease or acute injury. In this setting, five additional criteria were considered important: age, morning stiffness, radiographic osteophytes, radiographic joint space narrowing and concordance between symptoms and radiographic findings. The reliability and validity were very good. Conclusion: Radiographic features were considered critical when determining whether a patient had symptoms due to hand OA. The consensus-based decision analysis approach in Phase 2 complemented the data-driven results from Phase 1, which will form the basis of the final classification criteria sets. Competing Interests: Competing interests: IKH reports personal fees from Abbvie and Novartis, and research grants from Pfizer and IMI-APPROACH (both paid to the institution), all outside of the submitted work. FB reports being CEO of 4MOVING BIOTECH, received personal fees from 4P PHARMA, Boehringer, Bone Therapeutics, CellProthera, Galapagos, GSK, Lilly, Merck Sereno, MSD, Novartis, Pfizer, Servier and Peptinov, and research grant from TRB Chemedica and IMI-APPROACH (paid to the institution), all outside the submitted work. GHB reports personal fees from Pfizer, Sobi, Fresenius, Mylan, Tedec Meiji, Novartis, Sandoz and Faes, outside of the submitted work. EM reports personal fees from Expanscience, Mylan-Meda, TRB Chemedica, Pierre Fabre, Celgene and Fidia, and non-financial support from Pfizer, outside the submitted work. CDM and JJE report a research grant from BMS, outside the submitted work. RR reports personal fees from Abbvie, Celgene, Novartis, Pfizer and Lilly, outside of the submitted work. TAS reports personal fees from Sanofi, AbbVie, Roche and Takeda, outside of the submitted work. ZS reports personal fees from AbbVie, Roche, Pfizer, Berlin Chemie, UCB and Bristol-Myers, outside of the submitted work. RW reports personal fees from Abbvie, Galapagos, UCB, Bristol Myers Squib and Tilman, and grants from Amgen, outside the submitted work. ME reports serving on an advisory board for Pfizer (tanezumab) and research grant from IMI-APPROACH (paid to the institution), outside of the submitted work. SB-Z reports personal fees from Infirst healthcare, Pfizer and Osteoarthritis and Cartilage, outside the submitted work. PH is a co-inventor of the 1000minds software used in this study. MK reports personal fees from Abbvie, Pfizer, Levicept, GlaxoSmithKline, Merck-Serono, Kiniksa, Flexion, Galapagos, Jansen, CHDR, Novartis and UCB, and research grants from Pfizer, IMI-APPROACH (all paid to the institution), and royalties from Wolters Kluwer and Springer Verlag, all outside the submitted work. YYL reports grants from National Medical Research Council of Singapore, and personal fees from Abbvie, DKSH, Janssen, Novartis and Pfizer, all outside the submitted work. (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu